Abraham G, Almeida A, Gaurav K, Khan MY, Patted UR, Kumaresan M. Reno protective role of amlodipine in patients with hypertensive chronic kidney disease. World J Nephrol 2022; 11(3): 86-95 [PMID: 35733653 DOI: 10.5527/wjn.v11.i3.86]
Corresponding Author of This Article
Mohammed Yunus Khan, MD, Medical Affairs, Dr. Reddys Labs, 7-1, 27, Ameerpet Road, Leelanagar, Ameerpet, Hyderabad 500016, Telangana, India. doctorkhan26@gmail.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. May 25, 2022; 11(3): 86-95 Published online May 25, 2022. doi: 10.5527/wjn.v11.i3.86
Reno protective role of amlodipine in patients with hypertensive chronic kidney disease
Georgi Abraham, A Almeida, Kumar Gaurav, Mohammed Yunus Khan, Usha Rani Patted, Maithrayie Kumaresan
Georgi Abraham, Department of Nephrology, MGM Healthcare, Nelson Manickam Road, Aminjikarai, Chennai 6300028, India
A Almeida, PD Hinduja Hospital and Medical Research Center, Almeida, A (reprint author), PD Hinduja, Hinduja Clin, Dept Med, Nephrol Sect, 2209 Veer Savarkar Marg, Bombay 400016, Maharashtra, Mumbai 400016, India
Kumar Gaurav, Mohammed Yunus Khan, Usha Rani Patted, Medical Affairs, Dr. Reddys Labs, Hyderabad 500016, Telangana, India
Maithrayie Kumaresan, Medical Affairs, Madras Medial Mission Hospital, Chennai 600037, India
Author contributions: Khan MY, Patted UR, and Gaurav K developed the concept and drafted the manuscript; All authors reviewed the manuscript and gave final approval.
Conflict-of-interest statement: Khan MY, Patted UR and Gaurav K are employees of Dr. Reddy’s Laboratories and may own stock. Abraham G, Almeida A, Kumaresan M are members of the advisory board for Dr. Reddy’s Laboratories.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohammed Yunus Khan, MD, Medical Affairs, Dr. Reddys Labs, 7-1, 27, Ameerpet Road, Leelanagar, Ameerpet, Hyderabad 500016, Telangana, India. doctorkhan26@gmail.com
Received: May 28, 2021 Peer-review started: May 28, 2021 First decision: July 31, 2021 Revised: August 23, 2021 Accepted: April 2, 2022 Article in press: April 2, 2022 Published online: May 25, 2022 Processing time: 360 Days and 23.6 Hours
Abstract
Chronic kidney disease (CKD) and hypertension (HTN) are closely associated with an overlapping and intermingled cause and effect relationship. Decline in renal functions are usually associated with a rise in blood pressure (BP), and prolonged elevations in BP hasten the progression of kidney function decline. Regulation of HTN by normalizing the BP in an individual, thereby slowing the progression of kidney disease and reducing the risk of cardiovascular disease, can be effectively achieved by the anti-hypertensive use of calcium channel blockers (CCBs). Use of dihydropyridine CCBs such as amlodipine (ALM) in patients with CKD is an attractive option not only for controlling BP but also for safely improving patient outcomes. Vast clinical experiences with its use as monotherapy and/or in combination with other anti-hypertensives in varied conditions have demonstrated its superior qualities in effectively managing HTN in patients with CKD with minimal adverse effects. In comparison to other counterparts, ALM displays robust reduction in risk of cardiovascular endpoints, particularly stroke, and in patients with renal impairment. ALM with its longer half-life displays effective BP control over 24-h, thereby reducing the progression of end-stage-renal disease. In conclusion, compared to other classes of CCBs, ALM is an attractive choice for effectively managing HTN in CKD patients and improving the overall quality of life.
Core Tip: Amlodipine (ALM) is a powerful, well-tolerated, and safe anti-hypertensive agent widely used alone or as a key component of combination therapy for hypertension in chronic kidney disease (CKD). Its effectiveness in reducing blood pressure has proven benefits in cardiovascular event reduction and progression of renal disease. Overall, ALM emerges as the drug of choice in comparison to the newer calcium channel blockers in terms of its effectiveness and potency in BP lowering in CKD patients.
